{"id":"NCT00191945","sponsor":"Eli Lilly and Company","briefTitle":"Efficacy and Safety of Atomoxetine in Children With Recent Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD)","officialTitle":"A Randomized Double-Blind, Placebo-Controlled Clinical Trial of Efficacy and Safety of Atomoxetine up to 12 Weeks in Newly Diagnosed Children and Adolescents Outpatients With Attention-Deficit/Hyperactivity Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-05","primaryCompletion":"2008-02","completion":"2008-02","firstPosted":"2005-09-19","resultsPosted":"2010-01-26","lastUpdate":"2010-02-02"},"enrollment":151,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Attention Deficit Hyperactivity Disorder"],"interventions":[{"type":"DRUG","name":"Atomoxetine Hydrochloride","otherNames":["LY139603","Strattera"]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"Atomoxetine","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Double blinded clinical trial placebo controlled in 153 children (planned enrollment) with recent diagnosis of ADHD. Patients will be randomized to atomoxetine or placebo arm (2:1). The double blinded period will last 12 weeks and the treatment open phase will last up to 1 year, and atomoxetine treatment will be administered.\n\nA gatekeeper strategy will be employed for sequentially testing the secondary objectives.","primaryOutcome":{"measure":"Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version:Investigator Administered and Scored (ADHDRS-IV-Parent:Inv) Total Score at 12 Week Endpoint","timeFrame":"Week 12","effectByArm":[{"arm":"Atomoxetine","deltaMin":26.3,"sd":12.7},{"arm":"Placebo","deltaMin":34.8,"sd":12.3}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":11,"countries":["Spain"]},"refs":{"pmids":["25019647","19785510","19519260"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":100},"commonTop":["Decreased appetite","Headache","Somnolence","Abdominal pain","Vomiting"]}}